Tao Yong, Ding Lei, Yang Guan Gen, Qiu Jian Ming, Wang Dong, Wang Hongtao, Fu Chao
Zhejiang Chinese Medicine University Affiliated No.3 Hangzhou Hospital, Hangzhou, China.
The Third People's Hospital of Hangzhou, Hangzhou, China.
Cancer Med. 2018 Jul;7(7):2876-2886. doi: 10.1002/cam4.1542. Epub 2018 May 15.
Increasing evidences reported that cancer-triggered inflammation was associated with survival prognosis from colorectal cancer (CRC). However, the comprehensive effects of inflammatory-based coNLR-PLR that combines neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) rarely remain to be determined during chemotherapy. We retrospectively analyzed clinical data and baseline laboratory parameters from 153 colorectal cancer patients who underwent palliative adjuvant chemotherapy between January 2009 to January 2012. Receiver operating characteristic (ROC) curves and linear regression analyzed the predictive ability of NLR, and PLR for calculating the score of coNLR-PLR. Overall survival (OS) and recurrence-free survival (RFS) rates were estimated using the Kaplan-Meier method and analyzed by the Cox proportional hazards model in univariate and multivariate analysis. The optimal cut-off value of NLR and PLR was 2.24 and 186 by the ROC analysis. Kaplan-Meier method showed that patients with high coNLR-PLR score was associated with poorer OS and RFS (all P < .05). In univariate and multivariate analysis, it obtained that the coNLR-PLR severed as a strong independent prognostic factor for OS and RFS (all P < .05). These results highlight that coNLR-PLR index severed as a strong predictor of prognosis biomarker in CRC patients receiving adjuvant chemotherapy. Furthermore, its assessment could contribute to accurately predicting prognosis after chemotherapy in clinical practice.
越来越多的证据表明,癌症引发的炎症与结直肠癌(CRC)的生存预后相关。然而,在化疗期间,将中性粒细胞与淋巴细胞比值(NLR)和血小板与淋巴细胞比值(PLR)相结合的基于炎症的联合NLR-PLR的综合影响仍有待确定。我们回顾性分析了2009年1月至2012年1月期间接受姑息性辅助化疗的153例结直肠癌患者的临床资料和基线实验室参数。采用受试者工作特征(ROC)曲线和线性回归分析NLR和PLR对计算联合NLR-PLR评分的预测能力。采用Kaplan-Meier法估计总生存(OS)率和无复发生存(RFS)率,并通过Cox比例风险模型进行单因素和多因素分析。ROC分析得出NLR和PLR的最佳截断值分别为2.24和186。Kaplan-Meier法显示,联合NLR-PLR评分高的患者OS和RFS较差(所有P<0.05)。在单因素和多因素分析中,发现联合NLR-PLR是OS和RFS的强独立预后因素(所有P<0.05)。这些结果表明,联合NLR-PLR指数是接受辅助化疗的CRC患者预后生物标志物的强预测指标。此外,其评估有助于在临床实践中准确预测化疗后的预后。